Literature DB >> 21710498

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.

Chuan-Hai Zhang1, Ge-Liang Xu, Wei-Dong Jia, Jian-Sheng Li, Jin-Liang Ma, Yong-Sheng Ge.   

Abstract

Available literature on the effects of interferon (IFN) treatment on development and progression of hepatocellular carcinoma (HCC) in patients with chronic virus infection reports controversial results. The primary objective of this meta-analysis was to evaluate the effect of IFN on HCC risk in patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection; IFN's efficacy on local tumor progression and survival of advanced HCC patients was also assessed. All randomized controlled trials (RCTs) comparing IFN with no antiviral treatment were selected. Finally, we identified 11 RCTs including 1,772 patients, who met our inclusion criteria to perform this meta-analysis. Our analysis results showed that IFN significantly decreased the overall HCC incidence in HCV-infected patients [relative risk (RR)=0.39; 95% confidence interval (CI)=0.26-0.59; p=0.000], subgroup analysis indicated that IFN decreased HCC incidence in HCV-related cirrhotic patients evidently (RR=0.44; 95% CI=0.28-0.68; p=0.000); but HCC incidence in nonresponders to initial antiviral therapy did not reduce by maintenance IFN therapy (RR=0.96; 95% CI=0.59-1.56; p=0.864). Analysis results also demonstrated that IFN did not significantly affect the overall rate of HCC in HBV-infected patients although there was a trend favoring IFN therapy (RR=0.23; 95% CI=0.05-1.04; p=0.056). Besides, IFN did not improve one-year overall survival of advanced HCC patients significantly (RR=1.61; 95% CI=0.96-2.69; p=0.072); however, a quantitative analysis on local tumor progression could not be performed owing to lack of unified definitions among trials included in our study. By this meta-analysis, we conclude that IFN therapy is effective in reducing overall HCC risk in chronic HCV-infected patients; using it in this subpopulation seems promising, but its administration in other subpopulations still requires further exploration.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710498     DOI: 10.1002/ijc.25767

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Chemopreventive strategies in hepatocellular carcinoma.

Authors:  Siddharth Singh; Preet Paul Singh; Lewis R Roberts; William Sanchez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-13       Impact factor: 46.802

Review 2.  Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.

Authors:  Jian-Hong Zhong; Qing-Lian Zhong; Le-Qun Li; Hang Li
Journal:  Tumour Biol       Date:  2014-08-14

3.  Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Tsutomu Tamai; Hirofumi Uto; Yoichiro Takami; Kouhei Oda; Akiko Saishoji; Masashi Hashiguchi; Kotaro Kumagai; Takeshi Kure; Seiichi Mawatari; Akihiro Moriuchi; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

Review 4.  Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.

Authors:  Akinobu Tawada; Tatsuo Kanda; Fumio Imazeki; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2016-03-29       Impact factor: 6.047

Review 5.  Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C.

Authors:  Hirayuki Enomoto; Shuhei Nishiguchi
Journal:  World J Hepatol       Date:  2015-11-18

6.  All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.

Authors:  Eric Dieperink; Christine Pocha; Paul Thuras; Astrid Knott; Samuel Colton; Samuel B Ho
Journal:  Dig Dis Sci       Date:  2014-02-15       Impact factor: 3.199

Review 7.  Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.

Authors:  Yasushi Seo; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

8.  Therapeutic strategies for hepatocellular carcinoma: new advances and challenges.

Authors:  Sílvia Vilarinho; Tamar Taddei
Journal:  Curr Treat Options Gastroenterol       Date:  2015-06

9.  Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis.

Authors:  Maja Thiele; Lise L Gluud; Emilie K Dahl; Aleksander Krag
Journal:  BMJ Open       Date:  2013-08-14       Impact factor: 2.692

10.  Correlation between vitamin D levels and apoptosis in geriatric patients infected with hepatitis C virus genotype 4.

Authors:  Sami A Gabr; Ahmad H Alghadir; Ahmed A Allam; Jamaan Ajarem; Ghada Al-Basher; Mostafa A Abdel-Maksoud; Ayman A Ghfar; Alaa Aboud
Journal:  Clin Interv Aging       Date:  2016-05-04       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.